CYP3A4 has been reported to be the most impacted isoform in inflammation-related P450 down-regulation, which might lead to lower metabolism, prolonged half-life, and increased plasma concentration of CYP3A4 substrate drugs used for COVID-19 treatment (Deb and Arrighi, 2021). This evidence concerns the gene CYP2B6 and COVID-19.